NCT06939686 Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2024-11-01 with a primary completion date of 2026-07-31.

Brief Summary

This study is a prospective, randomized controlled trial designed to evaluate the effectiveness of Miro3D Wound Matrix plus Standard of Care (SOC) compared to SOC alone in treating Wagner Grade 1 diabetic foot ulcers (DFUs) and wound dehiscence in an outpatient setting. The trial is sponsored by Reprise Biomedical, Inc. and aims to explore whether the addition of Miro3D-a three-dimensional, acellular porcine-derived wound matrix-enhances wound healing outcomes compared to SOC alone. Purpose of the Study: The primary purpose of the study is to determine whether applying Miro3D in combination with SOC leads to improved healing of diabetic foot ulcers compared to SOC alone. Specifically, the study seeks to assess early wound healing progress at four weeks (as measured by percent area reduction and granulation tissue formation) as a predictor of complete healing by twelve weeks. Key Question the Study Seeks to Answer: Does the addition of Miro3D to standard wound care improve the healing rate and overall wound outcomes for patients with Wagner Grade 1 diabetic foot ulcers or dehisced wounds compared to standard care alone? Study Design Overview: Subjects who meet inclusion/exclusion criteria will be randomized into one of two groups: 1. Miro3D + SOC arm - receiving Miro3D weekly for 4 weeks, then biweekly if needed, for up to 12 weeks. 2. SOC alone (control) arm - receiving SOC without Miro3D. If the wound remains unhealed at 12 weeks in the SOC alone arm, participants may "crossover" to receive Miro3D treatment under the same schedule for an additional 12 weeks. Primary Endpoint: 1\. Percent Area Reduction (PAR) and granulation tissue formation at 4 weeks, serving as predictors for wound healing at 12 weeks. Secondary Endpoints: 1. Quality of Life (QOL) improvements, including pain, mobility, and emotional well-being, assessed using a validated Wound/Ulcer-QOL tool. 2. Pain levels using a Visual Analog Scale (VAS) at each visit. Population: Approximately 30 adult subjects (15 per arm) with Wagner Grade 1 diabetic foot ulcers or dehisced wounds will be enrolled. Subjects must have adequate blood flow, demonstrate wound size criteria, and commit to offloading and follow-up care. Follow-Up: Subjects will be followed weekly through the 12-week study period. Healed subjects will undergo confirmation visits at 2 and 4 weeks post-closure. Subjects in the crossover arm will be followed for an additional 12 weeks if their wound was unhealed at the primary endpoint. Statistical Considerations: Data will be summarized using descriptive statistics, including wound measurements, infection status, and healing rates. Comparative analysis will be conducted between treatment groups and schedules (weekly vs. biweekly Miro3D application). Adverse events (AEs), serious adverse events (SAEs), and device-related events will also be documented. This study aims to generate clinical evidence supporting the use of Miro3D as a beneficial adjunct to standard wound care in promoting early and complete healing of diabetic foot ulcers.

Eligibility Criteria

Inclusion Criteria: 1. Must be at least 18 years of age and capable of providing informed consent. 2. Must have a full- or partial-thickness Wagner Grade 1 ulcer or wound on the foot; if involving the malleolus, no more than 50% of the wound may be above the midpoint of the medial malleolus. 3. Index wound/ulcer must be between 1 cm² and 20 cm² post-debridement. 4. Wound/ulcer must have been present for at least 4 weeks prior to screening. 5. Adequate circulation must be documented by one of the following: ABI between 0.7-1.2, TBI ≥ 0.7, TCPO2 ≥ 40 mmHg, or triphasic/biphasic Doppler waveforms. 6. Other wounds, if present, must be at least 2 cm from the index wound/ulcer. 7. Any previous infections must have been adequately treated per IDSA guidelines. 8. Subjects must agree to proper offloading and/or compression, have a stable living environment, and be able to attend follow-up visits. 9. Must provide written consent for digital imaging. 10. For Miro3D arm: Index wound/ulcer must have a clean base free of devitalized tissue or debris at the time of product placement. Exclusion Criteria: 1. Index wound/ulcer has reduced ≥30% after two weeks of SOC from screening to baseline. 2. Poorly controlled diabetes (HbA1c ≥ 12%). 3. Active, untreated or uncontrolled osteomyelitis. 4. Malignancy or vasculitis at the wound site. 5. Undergoing chemotherapy. 6. On dialysis. 7. Use of investigational drugs or therapies within 30 days prior to screening. 8. Conditions that would compromise study participation or adherence. 9. Known sensitivity to porcine materials. 10. Third-degree burns. 11. Worsening ischemia or gangrene at screening. 12. History of radiation to the wound site. 13. Exposed internal fixation, implants, or hardware in the wound. 14. Patient is transitioning to palliative or comfort care.

Contact & Investigator

Frequently Asked Questions

Related Trials